Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

ClinicalTrials.gov ID: NCT01879319

Public ClinicalTrials.gov record NCT01879319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).

Study identification

NCT ID
NCT01879319
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Amgen
Industry
Enrollment
164 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 11, 2013 (Actual)
Primary completion
Nov 15, 2013 (Actual)
Completion
Not listed
Last update posted
Nov 30, 2022

Started 2013

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
21
Facility City State ZIP Site status
Research Site Phoenix Arizona 85020 —
Research Site Encino California 91436 —
Research Site Thousand Oaks California 91360 —
Research Site Tustin California 92780 —
Research Site Ventura California 93003 —
Research Site Port Charlotte Florida 33952 —
Research Site Saint Augustine Florida 32086 —
Research Site Atlanta Georgia 30328 —
Research Site Atlanta Georgia 30342 —
Research Site Gainesville Georgia 30501 —
Research Site Lexington Kentucky 40504 —
Research Site Lewiston Maine 04240 —
Research Site Ayer Massachusetts 01432 —
Research Site Manlius New York 13104 —
Research Site Cadiz Ohio 43907 —
Research Site Marion Ohio 43302 —
Research Site Duncansville Pennsylvania 16635 —
Research Site Lansdale Pennsylvania 19446 —
Research Site Jackson Tennessee 38305 —
Research Site Nashville Tennessee 37203 —
Research Site Austin Texas 78731 —
Research Site Dallas Texas 75231 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01879319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 30, 2022 · Synced Oct 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01879319 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →